Conversion of poorly immunogenic malaria repeat sequences into a highly immunogenic vaccine candidate

Vaccine

Volumn 20, Issue 5-6, 2001, Pages 771-788

  Milich, David R ^a   Hughes, Janice ^a   Jones, Joyce ^a   Sällberg, Matti ^b   Phillips, Tom R ^a  

^a Vaccine Research Institute of San Diego   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

HBcAg; Malaria; Pre erythrocytic; Vaccine

Indexed keywords

CD4 ANTIGEN; EPITOPE; HEPATITIS B CORE ANTIGEN; HEPATITIS B CORE ANTIGEN CIRCUMSPOROOITE PROTEIN; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; MALARIA VACCINE; MONOCLONAL ANTIBODY; RECOMBINANT ANTIGEN; UNCLASSIFIED DRUG; V12 PF3 1 ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGENICITY; ARTICLE; B LYMPHOCYTE; CELL SPECIFICITY; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; FEMALE; HUMORAL IMMUNITY; IMMUNOGENICITY; MALARIA; MOUSE; NONHUMAN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; SPOROZOITE; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; EPITOPES; FEMALE; HEPATITIS B CORE ANTIGENS; KINETICS; MALARIA VACCINES; MICE; MICE, TRANSGENIC; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; RECEPTORS, ANTIGEN, T-CELL; REPETITIVE SEQUENCES, AMINO ACID; T-LYMPHOCYTES; VACCINES, SYNTHETIC;

EID: 0035852348     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(01)00400-5     Document Type: Article

References (71)

1. Pathways and strategies for developing a malaria blood-stage vaccine
2. Rationale for the development of an engineered sporozoite malaria vaccine
3. Protective immunity produced by the injection of X-irradiated sporozoites of Plasmodium berghei
4. Sporozoite-induced immunity in mammalian malaria: A review
5. Immunization of monkeys against Plasmodium cynomolgi by X-irradiated sporozoites
6. Immunization of man against falciparum and vivax malaria by use of attenuated sporozoites
7. Effect of various routes of immunization and methods of parasite attenuation on the development of protection against sporozoite-induced rodent malaria
8. Monovalent fragments (Fab) of monoclonal antibodies to a sporozoite surface antigen (Pb44) protect mice against malarial infection
9. Hybridoma produces protective antibodies directed against the sporozoite stage of malaria parasite
10. Synthetic peptide vaccine confers protection against murine malaria
11. Circumsporozoite proteins of malaria parasites contain a single immunodominant region with two or more identical epitopes
12. Rationale for development of a synthetic vaccine against Plasmodium falciparum malaria
13. + T cells and antibodies required for immunity to malaria sporozoites
14. Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria
15. + T cell, interferon-γ, and nitric oxide dependent immunity
16. Sporozoite vaccine induces genetically restricted T-cell elimination of malaria from hepatocytes
17. Improving protective immunity induced by DNA-based immunization: Priming with antigen and GM-CSF-encoding plasmid DNA and boosting with antigen-expressing recombinant poxvirus
18. Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine
19. Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites
20. Assessment in humans of a synthetic peptide-based vaccine against the sporozoite stage of the human malaria parasite, Plasmodium falciparum
21. Naturally acquired antibodies to sporozoites do not prevent malaria: Vaccine development implications
22. Phase I clinical trial of a recombinant malaria vaccine consisting of the circumsporozoite repeat region of Plasmodium falciparum coupled to hepatitis B surface antigen
23. Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine
24. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria
25. Long-term efficacy and immune responses following immunization with the RTS, S malaria vaccine
26. CS protein-specific opsonizing antibodies induced by the RTS,S malaria vaccine mediate protection
27. The nucleocapsid of the hepatitis B virus is both a T-cell independent and a T-cell dependent antigen
28. The hepatitis B nucleocapsid as a vaccine carrier moiety
29. Immunity to malaria elicited by hybrid hepatitis B virus core particles carrying circumsporozoite protein epitopes
30. Immunization with hybrid hepatitis B virus core particles carrying circumsporozoite antigen epitopes protects mice against Plasmodium yoelii challenge
31. + T-cell repertoire in chronic hepatitis B virus infection
32. The position of heterologous epitopes inserted in hepatitis B virus core particles determines their immunogenicity
33. Binding of malaria T cell epitopes to DR and DQ molecules in vitro correlates with immunogenicity in vivo: Identification of a universal T cell epitope in the P. falciparum CS protein
34. Human T-cell recognition of the circumsporozoite protein of Plasmodium falciparum: Immunodominant T-cell domains map to the polymorphic regions of the molecule
35. Determination of the fold of the core protein of hepatitis virus by electron cryomicroscopy
36. Visualization of a 4-helix bundle in the hepatitis B virus capsid by cryo-electron microscopy
37. + clones from a malaria-immunized volunteer
38. Immunogenicity of multiple antigen peptides (MAP) containing T and B cell epitopes of the repeat region of the P. falciparum circumsporozoite protein
39. General method for the rapid solid-phase synthesis of large numbers of peptides: Specificity of antigen-antibody interaction at the level of individual amino acids
40. Rapid "tea-bag" peptide synthesis using 9-fluorenylmethoxycarbonyl (Fmoc) protected amino acids applied for antigenic mapping of viral proteins
41. Immunochemical structure of hepatitis B e antigen in the serum
42. Demonstration of two distinct antigenic determinants on hepatitis B e antigen by monoclonal antibodies
43. The structure of hepadnaviral core antigens: Identification of free thiols and determination of the disulfide bonding pattern
44. A protease-sensitive hinge linking the two domains of the hepatitis B virus core protein is exposed on the viral capsid surface
45. Phenotypic mixing between different hepadnavirus nucleocapsid proteins reveals C protein dimerization to be cis preferential
46. Comparative immunogenicity of hepatitis B virus core and e antigens
47. Hepatitis B virus capsid particles are assembled from core-protein dimer precursors
48. The hepatitis B virus core and e antigens elicit different Th cell subsets: Antigen structure can affect Th cell phenotype
49. Plasmodium falciparum polyoximes: Highly immunogenic synthetic vaccines constructed by chemoselective ligation of repeat B-cell epitopes and a universal T-cell epitope of CS protein
50. T cell-independent type I antibody response against B cell epitopes expressed repetitively on recombinant virus particles
51. Genetic control of the immune response in mice to a Plasmodium falciparum sporozoite vaccine: Widespread non-responsiveness to a single malaria T epitope in highly repetitive vaccine
52. + T cells from a sporozoite-immunized volunteer recognize the P. falciparum CS protein
53. Localization of HLA-AS.1-restricted T cell epitopes in the circumsporozoite protein of Plasmodium flaciparum
54. Role of B cells in antigen presentation of the hepatitis B core
55. Molecular basis for the interaction of the hepatitis B virus core antigen with the surface immunoglobulin receptor on naïve B cells
56. Hepatitis B virus core antigen binds and activates naïve human B cells in vivo: Studies with a human PBL-NOD/SCID mouse model
57. Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis
58. A new hepatitis B vaccine containing HBeAg in addition to HBsAg
59. Hepatitis B virus antigen made in microbial cells immunize against viral infection
60. Possible role of immune responses to HBcAg in protection against hepatitis B infections
61. Antibody production to the nucleocapsid and envelope of the hepatitis B virus primed by a single synthetic T cell site
62. + T cell clones obtained from Plasmodium falciparum sporozoite-immunized volunteers recognize polymorphic sequences of the circumsporozoite protein
63. Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine
64. + cytolytic T cell clone confers protection against murine malaria
65. + T cell clones against Plasmodium yoelii liver stages
66. The complexity of protective immunity against liver-stage malaria
67. Inhibition of development of exoerythrocytic forms of malaria parasites by γ-interferon
68. + T cells
69. Sterile protection of monkeys against malaria after adminitration of interleukin-12
70. Inhibition of entry of Plasmodium falciparum and P. vivax sporozoites into cultured cells: An in vitro assay of protective antibodies
71. Congenital transfer of antibodies against malarial sporozoites detected in Gambian infants